Corona in huisdierenvaccins

Te verwachten is dat op den duur nog meer zaken aangepakt moeten worden waar we van houden en ons goed doen. In t nieuws is af en toe summier wat gezegd over huisdieren en corona, dat ze t kunnen hebben en overdragen. Ik had in mei al eens n post van iemand gezien dat er n streng van corona in vaccins zit en ben dat gaan uitzoeken. En ja hoor.

NOBIVAC https://mcvoordieren.nl/kennisbank/inentingen-hond/

Hondengriep 2009

http://www.nobivac.com/about-nobivac-history-of-innovation.aspx

https://www.drugs.com/vet/nobivac-canine-flu-h3n8.html#

http://www.nobivac.com/about-nobivac-novibac-around-the-globe.aspx

Onderdeel van Merc

https://www.merck-animal-health-usa.com/nobivac/partnership

Met n corona vaccin voor honden

https://www.merck-animal-health-usa.com/nobivac/nobivac-canine-1-cv

Ik kan niet inloggen bij Product Label om op te zoeken wanneer dit gemaakt is.

Corona(registrated trademark) 􀓞

https://www.drugs.com/vet/corona-fung-a-way.html#

Warnings

● Contains gentamicin as a preservative.

● Vaccinate only healthy, non-parasitized dogs.

● Do not vaccinate pregnant bitches.

● The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction

https://www.drugs.com/vet/nobivac-canine-1-cv.html

For patent information:

http://www.merck.com/product/patent/home.html

(sws interessant om te kijken waar ze allemaal vaccins voor hebben en wat voor uitbraken er zijn geweest)

25×1 DOSE

065284

344040-03

Als ik op die code zoek kom ik hier:

Argentinië. Compositions and methods using RNA interference CDPK type for controlling nematodes (rondwomen)􀓞

Application ARP080100568A events

2007-02-09

Priority to US90046607P

2008-02-08

Application filed by Basf 􀓞

Plant Science Gmbh

2009-05-27

Publication of AR065284A1

DsRNA compositions and transgenic plants capable of inhibiting the expression of genes essential for establishing or maintaining a plant nematode infestation, and methods associated with those. Specifically it relates to the use of RNA interference to inhibit the expression of a gene plant white, which is a gene (le type CDPK, and is related to generation of plants having increased resistance to parasitic nematodes claim 1. A molecule dsRNA characterized by comprising i) a first strand comprising a sequence substantially identical to a portion of a gene CDPK type, and ii) a second chain comprising a sequence substantially complementary to the first strand, wherein the portion of the gene CDPK type is a polynucleotide selected from the group consisting of (lees verder) Een dieren-en veearts weten dit vast.

https://patents.google.com/patent/AR065284A1/en?oq=065284

Zoekende kwam ik op deze, okt. 2003. Uiteraard bestaat corona al langer maar n patent… de namen zijn ook interessant en dat t van Chiron group is.

https://pubchem.ncbi.nlm.nih.gov/patent/US2006257852

En toen kwam ik ook op deze site waar t ontkracht wordt dat t iets met de Pirbright institute te

maken heeft maar de registratie leidde me hier naartoe en er staat interessante info op:

https://patents.justia.com/patent/10130701

Terug bij de huisdieren: https://www.drugs.com/vet/recombitek-canine-corona-mlv.html#

RECOMBITEK:

Active ingrediënt, corona virus, is n product van:

https://www.boehringer-ingelheim.com/animal-health/companion-animals-products/recombitek

Hoofdkantoor in Ingelheim met The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 175 affiliates and some 51,000 employees.

https://www.boehringer-ingelheim.com/locations/europe

Op deze pagina kun je dit document downloaden https://www.boehringer-ingelheim.com/science/human-health/research-and-development-pipeline

Daar staat dit op: Covid 19 iARDS Indiced Acute Respiratory Distress Syndrome

En uiteraard kan hier Gates niet ontbreken

https://www.boehringer-ingelheim.com/search/node/Gates

https://www.boehringer-ingelheim.com/covid-19/fighting-covid-19/global-access-commitment-with-gates-foundation

https://www.boehringer-ingelheim.com/press-release/fight-against-covid-19-pandemic-shapes-global-business-activities

Tekst zegt al genoeg, gepubliceerd in april 2020, ze waren er vlot bij:

2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic Solid performance in previous years strengthened the basis for absorbing the effects of COVID-19 spreading; production continues at a high level Strong development pipeline; 18.2% of net sales invested in R&D

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities

Boehringer Ingelheim:

Production continues at a high level

Ingelheim, Germany, April 8, 2020 – Boehringer Ingelheim has stepped up its efforts in the fight against the COVID-19 pandemic. The company is offering support and relief through multiple initiatives under its Global Support Program, backed by strong business performance in previous years, including 2019. This strong basis also allows the company to maintain its investment levels to ensure further discovery, development, production and supply of highly innovative medicines that are needed by patients around the globe.

“As a research-driven pharmaceutical company, Boehringer Ingelheim is an active partner in the global movement to fight COVID-19. We are pleased that our business performance last year allows us to contribute to finding solutions to combat the virus,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “At the same time, we remain fully dedicated to reliable drug supply. And we are also working hard to minimize the impact of the pandemic on our global research and development programs…

Boehringer Ingelheim actively engages in the fight against COVID-19 through Global Support Program

Millions of patients around the world are dependent on the company’s medicines. Boehringer Ingelheim is doing everything possible to keep production for all medications running and to secure delivery. This also includes the supply of treatments to pet and livestock owners for their animals.

Over the past decades, Boehringer Ingelheim has gained considerable knowledge in various therapeutic areas, such as respiratory diseases and virology. Building on this know-how and experience, the company is engaged in several activities to find medical solutions to the pandemic, together with academic researchers, public institutions, international consortia, and other members of the biopharma industry.

Scientists at Boehringer Ingelheim are currently searching for novel virus-neutralizing antibodies. The company is screening its entire molecule library for compounds that could target the virus. Furthermore, Boehringer Ingelheim actively participates with its COVID-19 projects in several research consortia, the Innovative Medicines Initiative of the European Union and an initiative led by the Bill and Melinda Gates Foundation, for example. Besides the significant research contribution, other elements of the Global Support Program include a EUR 5.8 million donations fund, paid leave for its 51,000 employees to volunteer for COVID-19 relief, and a EUR 580,000 relief fund for social entrepreneurs and their communities in Kenya and India, supported by the company through its Making More Health program.

Strong performance in 2019 strengthens capital base The COVID-19 Global Support Program follows a strong business performance in 2019.

Adjusted for currency effects, net sales increased by 5.7% year on year to EUR 19 billion. To drive long-term growth, Research and Development (R&D) investments increased by 9.4% to nearly EUR 3.5 billion, or 18.2% of net sales, mainly driven by new products and pipeline advances in existing projects.

High liquidity and equity base In 2019, the company invested a record EUR 1.1 billion (2018: EUR 950 million) in fixed assets. Operating income at the Boehringer Ingelheim Group level rose by around 9% to EUR 3.8 billion, while net income after tax increased to EUR 2.7 billion (2018: EUR 2.1 billion). Cash flow from operating activities increased by EUR 356 million to EUR 3.3 billion. At the end of 2019, the equity ratio was at 44% (2018: 40%).

“Our solid capital base has allowed us to shield our operations and workforce from the impact of COVID-19,” said Michael Schmelmer, Member of the Board of Managing Directors with responsibility for Finance and Group Functions (lees verder op pagina)

https://www.boehringer-ingelheim.com/press-release/2019-performance-stronger-foundation-absorb-global-effects-covid-19-pandemic

En toen bleef mijn oog hangen op deze Dr. Dr. Monica Cheng werkt ook voor:

https://www.boehringer-ingelheim.com/partnering/connect-with-us/contact-us/our-team

Die gevestigd zijn in biberach, ingelheim, ridgefield, wenen, tokyo en shanghai.

Ze werkt ook met deze organisatie:

Alle projecten van hen op n rij, goh waar houden ze zich nu toch mee bezig:

Even zoeken op wat bekende organisaties en toen kwam ik bij WHO op deze pagina.

Sws interessant om de foto’s op te slaan om achter de echte namen te komen en dus n ogenschijnlijke Duitse boevenbende tegen te komen, maar scroll vooral even naar beneden.

Wordt vervolgd.